<DOC>
	<DOC>NCT01228344</DOC>
	<brief_summary>The purpose of this study is to describe the pediatric and adult patients (U.S. and foreign residents) diagnosed with malaria and treated with artemether-lumefantrine with regard to their demographics, including evaluation of their malaria immune status, treatment effectiveness, prior and concomitant medication use, and the occurrence of adverse events in association with artemether-lumefantrine treatment, based on the information collected in the CDC Malaria Case Surveillance Report Form.</brief_summary>
	<brief_title>Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<criteria>Any male or female infant, child or adult patient diagnosed with malaria who received artemetherlumefantrine and was reported to the CDC. Malaria may be clinically suspected or confirmed (microscopically, and/or by polymerase chain reaction [PCR], and/or rapid diagnostic test [RDT]).</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Artemether-lumefantrine</keyword>
	<keyword>demographics</keyword>
	<keyword>malaria</keyword>
</DOC>